Michael Krainock
Research Subjects
Michael Krainock has a total of 104 co-authors. Here are the top co-authors by number of shared publications:
- Minetta C. Liu
Mayo Clinic, Rochester, MN
34 shared publications - Andrew Stewart Poklepovic
Virginia Commonwealth University Health System, Richmond, VA
17 shared publications - Griffin L. Budde
Natera, Inc., Austin, Texas
17 shared publications - Alan Tan
Vanderbilt University Medical Center, Nashville, TN
16 shared publications - Bently Patrick Doonan
University of Florida 5 , Gainesville, Florida
16 shared publications - Daniel B. Flora
10St Elizabeth Cancer Center, Edgewood, Kentucky
16 shared publications
Latest Publications
- Open Access
- 7 October 2026
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 31 (11)
Whole-genome sequencing-based tumor-informed circulating tumor DNA monitoring for early detection of recurrence in patients with solid tumors
Background: Circulating tumor DNA (ctDNA) assays can transform patient management by enabling molecular residual disease (MRD) detection, prognosis prediction, and treatment monitoring. Here, we report clinical performance of Signatera Genome, a whole-genome sequencing (WGS)-based ctDNA assay, in a diverse pan-cancer cohort at landmark and longitudinal settings post-definitive treatment. Methods: We performed a retrospective analysis of 386 patients with one of the following cancers: breast, colorectal, non-small-cell lung, melanoma, or renal cell carcinoma. Signatera Genome assays, designed with high-quality variants selected from the matched tumor and normal WGS data, were used to detect ctDNA in the associated patients’ longitudinal plasma samples collected post-operatively. The correlation between ctDNA-based MRD status and systemic, distant recurrence-free survival (systemic DRFS) was assessed using Cox regression analysis. Results: In the pan-cancer cohort, landmark analysis at 3 months post-surgery revealed that patients with MRD-positivity had significantly inferior systemic DRFS compared to ctDNA-negative patients (hazard ratio [HR]: 23.7, P < .0001). Additionally, ∼30% improvement in 24-month systemic DRFS was observed among adjuvant-treated MRD-positive patients, whereas MRD-negative patients derived no clear benefit from adjuvant therapy. In the longitudinal setting, MRD positivity anytime post-definitive treatment surveillance significantly correlated with shorter systemic DRFS compared to serial MRD negativity (HR: 103.4, P < .0001). Tumor-specific analyses yielded similar findings. Notably, 62% (72/116) of patients had ctDNA detected in the ultra-sensitive range of <100 ppm. Conclusions: Our findings underscore the robust clinical performance of the Signatera Genome assay for MRD detection across solid tumors. Its broad applicability and high specificity support its integration into clinical practice and prospective trials.
- 7 October 2026
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 31 (11)
Open AccessWhole-genome sequencing-based tumor-informed circulating tumor DNA monitoring for early detection of recurrence in patients with solid tumors
Background: Circulating tumor DNA (ctDNA) assays can transform patient management by enabling molecular residual disease (MRD) detection, prognosis prediction, and treatment monitoring. Here, we report clinical performance of Signatera Genome, a whole-genome sequencing (WGS)-based ctDNA assay, in a diverse pan-cancer cohort at landmark and longitudinal settings post-definitive treatment. Methods: We performed a retrospective analysis of 386 patients with one of the following cancers: breast, colorectal, non-small-cell lung, melanoma, or renal cell carcinoma. Signatera Genome assays, designed with high-quality variants selected from the matched tumor and normal WGS data, were used to detect ctDNA in the associated patients’ longitudinal plasma samples collected post-operatively. The correlation between ctDNA-based MRD status and systemic, distant recurrence-free survival (systemic DRFS) was assessed using Cox regression analysis. Results: In the pan-cancer cohort, landmark analysis at 3 months post-surgery revealed that patients with MRD-positivity had significantly inferior systemic DRFS compared to ctDNA-negative patients (hazard ratio [HR]: 23.7, P < .0001). Additionally, ∼30% improvement in 24-month systemic DRFS was observed among adjuvant-treated MRD-positive patients, whereas MRD-negative patients derived no clear benefit from adjuvant therapy. In the longitudinal setting, MRD positivity anytime post-definitive treatment surveillance significantly correlated with shorter systemic DRFS compared to serial MRD negativity (HR: 103.4, P < .0001). Tumor-specific analyses yielded similar findings. Notably, 62% (72/116) of patients had ctDNA detected in the ultra-sensitive range of <100 ppm. Conclusions: Our findings underscore the robust clinical performance of the Signatera Genome assay for MRD detection across solid tumors. Its broad applicability and high specificity support its integration into clinical practice and prospective trials.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 7 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
Distribution of lead time between ctDNA detection and imaging-confirmed recurrence using the first ctDNA-positive sample prior to recurrence. Each dot represents an individual patient with green dots representing patients who became ctDNA-positive and whose initial post-positivity imaging remained negative with recurrence confirmed on subsequent imaging.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 7 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
Distribution of lead time between ctDNA detection and imaging-confirmed recurrence using the first ctDNA-positive sample prior to recurrence. Each dot represents an individual patient with green dots representing patients who became ctDNA-positive and whose initial post-positivity imaging remained negative with recurrence confirmed on subsequent imaging.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure 4 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
A, Kaplan–Meier RFS curves stratified by ctDNA status among patients who received adjuvant systemic therapy. Anytime ctDNA positivity was associated with significantly inferior RFS. B, Kaplan–Meier RFS curves stratified by ctDNA status among patients who did not receive adjuvant therapy, showing a similar strong association between ctDNA positivity and recurrence. C, Sankey diagram illustrating ctDNA dynamics after systemic therapy initiation among 53 patients with ≥1 on-treatment ctDNA timepoint. Of the 8 patients who recurred, 2 exhibited persistent ctDNA positivity or converted from ctDNA-negative to ctDNA-positive despite treatment. A subset demonstrated transient clearance before recurrence.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
A, Kaplan–Meier RFS curves stratified by ctDNA status among patients who received adjuvant systemic therapy. Anytime ctDNA positivity was associated with significantly inferior RFS. B, Kaplan–Meier RFS curves stratified by ctDNA status among patients who did not receive adjuvant therapy, showing a similar strong association between ctDNA positivity and recurrence. C, Sankey diagram illustrating ctDNA dynamics after systemic therapy initiation among 53 patients with ≥1 on-treatment ctDNA timepoint. Of the 8 patients who recurred, 2 exhibited persistent ctDNA positivity or converted from ctDNA-negative to ctDNA-positive despite treatment. A subset demonstrated transient clearance before recurrence.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
Representativeness of the study participants
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
Representativeness of the study participants
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
Overview plot of patients with stage IIIA melanoma.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
Overview plot of patients with stage IIIA melanoma.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
Overview plot of patients with stage IIB melanoma.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
Overview plot of patients with stage IIB melanoma.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
Overview plot of patients with stage IIA melanoma.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
Overview plot of patients with stage IIA melanoma.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure 5 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
Flow diagram depiction of ctDNA-driven changes in clinical management with representative case examples. Of the 190 patients included in our study, 34 had ctDNA positivity at any time point. Of these, clinical care was influenced by ctDNA positivity in 26 cases, ranging from imaging escalation to treatment initiation, switch, or escalation. MTM, mean tumor molecules; ND, not detected; NED, no evidence of disease; PR, partial response.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 5 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
Flow diagram depiction of ctDNA-driven changes in clinical management with representative case examples. Of the 190 patients included in our study, 34 had ctDNA positivity at any time point. Of these, clinical care was influenced by ctDNA positivity in 26 cases, ranging from imaging escalation to treatment initiation, switch, or escalation. MTM, mean tumor molecules; ND, not detected; NED, no evidence of disease; PR, partial response.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
Overview plot of patients with stage IA/B melanoma.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
Overview plot of patients with stage IA/B melanoma.